Eli Lilly’s Jaypirca pushes into first-line CLL, but commercial upside may be limited
Jaypirca; pirtobrutinib; Eli Lilly; chronic lymphocytic leukemia; CLL; small lymphocytic lymphoma; SLL; first-line treatment; second-line treatment; Bruin-CLL-314; Imbruvica; ibrutinib; BTK inhibitor; progression-free survival; FDA traditional approval; label expansion; market ceiling; oncology strategy
J&J-backed Cellular Origins raises $40M for cell therapy manufacturing
Cellular Origins; Johnson & Johnson; Series A; $40 million; cell therapy manufacturing; Constellation platform; robotic automation; ATMP; TTP Group; scalable manufacturing
FDA Broadens COVID-19 Vaccine Safety Probe to Adults Under New Health Leadership
FDA; COVID-19 vaccines; safety review; adults; Robert F. Kennedy Jr.; vaccine deaths; public trust; Pfizer; Moderna; myocarditis
UK cuts 2026 new-medicine rebate rate to 14.5% under VPAG
United Kingdom; VPAG; Voluntary Scheme for Branded Medicines Pricing Access and Growth; rebate rate; clawback rate; new medicines; NHS; drug pricing; pharmaceutical industry; 2026
PathAI’s AIM-MASH AI Assist Receives Historic FDA Qualification for MASH Clinical Trials
PathAI; AIM-MASH; AI Assist; FDA qualification; Drug Development Tool; biomarker qualification; MASH; MASLD; NASH; metabolic dysfunction-associated steatohepatitis; AI pathology; clinical trials; EMA qualification; liver biopsy; histology
Pluri Appoints Alejandro Weinstein as Chairman of the Board to Lead Strategic Shift and Unlock Value, Backed by Additional Investment
Pluri; Alejandro Weinstein; Chairman of the Board; strategic shift; additional investment; ownership increase; Zami Aberman; Vice Chairman; biotechnology; healthcare; M&A transactions; value creation; commercialization; corporate governance
Mindpeak Secures First Patent for Advanced AI Method in Digital Pathology
Mindpeak; digital pathology; AI-powered pathology; oncology diagnostics; cell classification; histopathology; EU patent; United Kingdom validation; AI model training; precision diagnostics
Spotlight On: 2026 Predictions – Where’s AI in Healthcare Heading?
AI in healthcare 2026; medical documentation AI; wearable technology healthcare; predictive analytics EHR; AI patient communication; healthcare operational efficiency; AI healthcare trends
Novartis and Relation Therapeutics form AI-driven, multi-program atopic disease collaboration
Novartis; Relation Therapeutics; AI-powered drug discovery; Lab-in-the-Loop; atopic diseases; immuno-dermatology; multi-program collaboration; asthma; allergies; eczema; allergic rhinitis; $55 million upfront; $1.7 billion milestones; functional cell atlases
Dyne Therapeutics Reports Positive Results for Duchenne Drug DYNE-251, Plans FDA Approval Submission
Dyne Therapeutics; DYNE-251; Duchenne muscular dystrophy; exon 51 skipping; DELIVER trial; FDA Breakthrough Therapy Designation; Biologics License Application; accelerated approval